| Literature DB >> 22713743 |
Imre Toth1, Geza Szucs, Tamas F Molnar.
Abstract
BACKGROUND: The tumorous infiltration or carcinosis of the pericardium could cause pericardial effusion in up to one-third of cases of malignancy, thus potentially interfere with the otherwise desirable oncological treatment. The existing surgical methods for the management of pericardial fluid are well-established but are not without limitations in the symptomatic relief of malignant pericardial effusion (MPE). The recurrence rate ranges between 43 and 69% after pericardiocentesis and 9 to 16% after pericardial drainage. The desire to overcome relative limitations of the existing methods led us to explore an alternative approach.Entities:
Mesh:
Year: 2012 PMID: 22713743 PMCID: PMC3485108 DOI: 10.1186/1749-8090-7-56
Source DB: PubMed Journal: J Cardiothorac Surg ISSN: 1749-8090 Impact factor: 1.637
Figure 1The position of patient and the place of incision of left side mediastinoscope-controlled parasternal pericardial fenestration.
Figure 2The place of pericardial window (left side).
Figure 3The intrapleural situation after parasternal pericardial fenestration (right side).
Different surgical methods for solving pericardial effusion in the examined period
| Percutaneous pericardiocentesis + drain | 23 |
| Subxyphoideal fenestration | 23 |
| Transdiaphragnatic pericardio-peritoneal fenestration | 2 |
| VATS pericardio-pleural fenestration | 2 |
| Thoracotomy, pericardio-pleural fenestration | 1 |
Figure 4The cumulative distribution of patients survival, and the lower and upper confidence bounds of cumulative distribution of survival after parasternal pericardial fenestration.
The demography, primary malignancy, operative time, hospital stay and the survival of the 22 patients operated with MCPF
| 1 | 51 | m | pulmonary | 20 | 11 | 131 | |
| 2 | 53 | m | pulmonary | 20 | 10 | 487 | |
| 3 | 68 | f | pulmonary | 30 | 10 | ? | |
| 4 | 53 | f | breast | 35 | 11 | 1207 | |
| 5 | 50 | f | ? | 50 | 9 | ? | |
| 6 | 46 | f | breast | 25 | 8 | ? | |
| 7 | 47 | m | pulmonary | 40 | 7 | 20 | |
| 8 | 72 | f | ? | 40 | 9 | 1275 | alive |
| 9 | 50 | f | breast | 40 | 10 | 135 | |
| 10 | 47 | m | pulmonary | 25 | 8 | ? | |
| 11 | 65 | m | pulmonary | 35 | 10 | 93 | |
| 12 | 71 | f | hematologic | 50 | 10 | 495 | |
| 13 | 57 | f | breast | 40 | 9 | 334 | |
| 14 | 54 | m | ? | 20 | 10 | 65 | |
| 15 | 26 | m | pulmonary | 20 | 11 | 231 | |
| 16 | 60 | m | pulmonary | 40 | 10 | 88 | |
| 17 | 73 | f | breast | 20 | 10 | 730 | alive |
| 18 | 59 | m | pulmonary | 30 | 11 | 173 | |
| 19 | 67 | f | pulmonary | 30 | 7 | ? | |
| 20 | 61 | f | breast | 25 | 7 | ? | |
| 21 | 68 | f | hematologic | 30 | 9 | ? | |
| 22 | 55 | m | pulmonary | 25 | 10 | ? | |
| | | | |||||
| SD | 11 | | | 9.5 | 1.3 | 413 | |
| | | | | ||||
| | | | SD pulmonary | 7.4 | 1.5 | 153 | |
| | | | | ||||
| SD breast | 8.6 | 1.5 | 473 |
*Statistically significant difference, p < 0.05.